Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2026 05:00 ET | Source: Italfarmaco

Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment

Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD communityNDS is based on Italfarmaco’s Phase 3 EPIDYS trial...
June 10, 2026 05:00 ET | Source: Italfarmaco

Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne

L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie...
June 02, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

An independent safety Data Monitoring Committee recommends the initiation of Cohort 2 in Entrada Therapeutics’ ELEVATE-45-201 study.
June 01, 2026 09:00 ET | Source: Muscular Dystrophy Association

MDA Expands 2026 Engage Symposium Series, Bringing the Neuromuscular Community Together in Four U.S. Cities

New York, June 01, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced its 2026 MDA Engage Symposium series, bringing free, in-person educational and community-building...
May 07, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics announces positive topline data from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study.
May 06, 2026 16:30 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Entrada Therapeutics will announce topline results from Cohort 1 of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026.
March 12, 2026 07:50 ET | Source: Muscular Dystrophy Association

The 2026 MDA Clinical & Scientific Conference Highlights Breakthroughs in Neuromuscular Research, Innovative Therapies, and Patient Care

Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees...
January 27, 2026 09:00 ET | Source: Muscular Dystrophy Association

Organizations Join Forces to Map How Human Muscle Regenerates

New York, Jan. 27, 2026 (GLOBE NEWSWIRE) -- A pivotal scientific collaboration born out of the Muscular Dystrophy Association’s (MDA) Muscle Regeneration Summit is advancing a first-of-its-kind...
January 08, 2026 07:00 ET | Source: Entrada Therapeutics, Inc.

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics reports progress across its portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.
December 10, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Announces More Than $2.7 Million For Research Grants to Advance Breakthroughs Across Neuromuscular Diseases

New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across...